Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy
- Cell Therapy Consortium
Research output: Contribution to journal › Article › peer-review
35
!!Link opens in a new tab
Scopus
citations